Lisaftoclax (APG-2575) is a medication being studied for its potential to help treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. It is being tested to see if it can improve the time patients live without their disease getting worse when used in combination with another medication.

Acalabrutinib is a medication that is already used to treat certain types of blood cancers, including chronic lymphocytic leukemia and small lymphocytic lymphoma. In this study, it is being used both alone and in combination with lisaftoclax to see if the combination can provide better outcomes for patients who have been previously treated with acalabrutinib.

Chronic Lymphocytic Leukemia – This is a type of cancer that affects the blood and bone marrow, characterized by the production of too many abnormal lymphocytes, a type of white blood cell. It progresses slowly and may not cause symptoms for years. Over time, the abnormal cells can crowd out healthy blood cells, leading to issues like anemia, infections, and bleeding problems. As the disease advances, it can spread to other parts of the body, including the lymph nodes, liver, and spleen. The progression can vary greatly among individuals, with some experiencing rapid changes and others remaining stable for long periods.

Small Lymphocytic Lymphoma – This is a type of non-Hodgkin lymphoma that primarily affects the lymph nodes, but it is closely related to chronic lymphocytic leukemia. It involves the slow accumulation of small, mature lymphocytes in the lymph nodes, which can lead to swelling and discomfort. The disease progresses slowly, often without symptoms in the early stages. As it advances, it can cause symptoms such as fatigue, night sweats, and weight loss. The abnormal lymphocytes can also spread to other organs, including the liver and spleen. The progression rate can vary, with some individuals experiencing a stable condition for years.